EUVIMEDEUVIMED entdecken
Crossref

Prediction of Clinical Response to Dupilumab for CRSwNP Based on the Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS) Score

Gian Marco Pace, Francesco Giombi iD, Francesca Pirola, Michele Cerasuolo, Enrico Heffler, Giovanni Paoletti, Francesca Puggioni, Giuseppe Mercante, Giuseppe Spriano, Luca Malvezzi

Annals of Otology, Rhinology & Laryngology · 2025-03 · 134 (3) · 201-210

DOI: 10.1177/00034894241300812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Otology, Rhinology & Laryngology, online erschienen am 19.11.2024. Verfasst von Gian Marco Pace und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Endoscopy, Sinusitis, Nasal Polyps. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Although the effectiveness of molecular antibodies has been established, evidence is still lacking on objective predictors of response. The aim of this study was to assess whether the extent of previous endoscopic sinus surgeries, assessed by means of the Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS) score, may influence clinical outcomes in refractory CRSwNP patients treated with dupilumab. Materials and Methods: A consecutive sample of patients treated with dupilumab for previously operated recalcitrant CRSwNP were enrolled in the study. Every patient was required to undergo a CT scan at baseline (T0), at 3 (T1), and 12 (T2) months after treatment start. ACCESS score was calculated at baseline, whilst at every timepoint patients underwent assessment of Nasal-Polyp-Score (NPS), Lund-Kennedy-Score (LKS), and had to fill in the 22-item Sinonasal-Outcome-Test (SNOT-22) and Visual-Analog-Scales (VAS) for sinonasal symptoms. Favorable outcome was considered based on EUFOREA guidelines, namely improving at least 3 of the followings: (i) NPS; (ii) SNOT-22; (iii) VAS-olfaction; and (iv) need for systemic corticosteroids.

Results

Overall favorable outcome was achieved in 69.1% (n = 38/55) of cases at T1, while in 89.1% (n = 49/55) at T2. There were no differences in baseline characteristics between responders and non-responders at both timepoints. At T1, out of all the included variables, no statistically significant predictor of favorable outcome was observed. Conversely, at T2, ACCESS score was the only confirmed independent predictive factor of response to dupilumab treatment (OR = 0.81 [95% CI = 0.67-0.92], P = .010).

Conclusions

Our findings suggest that the extent of previous endoscopic sinus surgeries may have a role in influencing clinical outcomes in patients with refractory CRSwNP undergoing treatment with dupilumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEndoscopySinusitisNasal PolypsRhinitisHumansMaleFemaleMiddle AgedTreatment OutcomeAdultAgedTomography, X-Ray ComputedParanasal Sinuses

Stichwörter der Autor:innen

ACCESSCRSwNPFESSendoscopic sinus surgerymolecular antibodiesrhinologytype-2 inflammation

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Surgery, The University of Auckland, Auckland, New Zealand.
  • Otorhinolaryngology Head & Neck Surgery Unit, Casa di Cura Humanitas San Pio X, Milan, Italy.
  • Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy.

ORCID-Profile: Francesco Giombi

Zitieren

APA

Pace, G. M., Giombi, F., Pirola, F., Cerasuolo, M., Heffler, E., Paoletti, G., Puggioni, F., Mercante, G., Spriano, G., & Malvezzi, L. (2025). Prediction of Clinical Response to Dupilumab for CRSwNP Based on the Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS) Score. Annals of Otology, Rhinology & Laryngology, 134(3), 201-210. https://doi.org/10.1177/00034894241300812

Vancouver

Pace GM, Giombi F, Pirola F, Cerasuolo M, Heffler E, Paoletti G, et al. Prediction of Clinical Response to Dupilumab for CRSwNP Based on the Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS) Score. Annals of Otology, Rhinology & Laryngology. 2025;134(3):201-210. doi:10.1177/00034894241300812

BibTeX
@article{Pace2025,
  author = {Pace, Gian Marco and Giombi, Francesco and Pirola, Francesca and Cerasuolo, Michele and Heffler, Enrico and Paoletti, Giovanni and Puggioni, Francesca and Mercante, Giuseppe and Spriano, Giuseppe and Malvezzi, Luca},
  title = {Prediction of Clinical Response to Dupilumab for CRSwNP Based on the Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS) Score},
  journal = {Annals of Otology, Rhinology & Laryngology},
  year = {2025},
  volume = {134},
  number = {3},
  pages = {201--210},
  doi = {10.1177/00034894241300812}
}
Kostenlos starten →